SIETES :: 92833 citas

Resultados de la búsqueda por ALZHEIMER REFINAR BÚSQUEDA

1.

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia. A nested case-control study. JAMA Intern Med 2019:24 de junio. [Ref.ID 103160]

2.

Jayadevappa R, Chhatre S, Malcowikz B, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Network Open 2019;2:e196562. [Ref.ID 103156]

3.

Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]

4.

Liu B, Luo Z, Pinto JM, Shiroma EJ, Tranah GJ, Wirdefeldt K, Fang F, Harris TB, Chen H. Relationship between poor olfaction and mortality among community-dwelling older adults: a cohort study. Ann Intern Med 2019:30 de abril. [Ref.ID 103093]

5.

Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ 2019;364:6 de marzo. [Ref.ID 103059]

6.

Jones G. GW Pharma's cannabis-based medicine to be tested in dementia. PMLiVE 2019:1. [Ref.ID 103025]

7.

Ranson JM, Kuzma E, Hamilton W, Muniz-Terrera G, Langa KM, Llewellyn DJ. Predictors of dementia misclassification when using brief cognitive assessments. Neurology: Clinical Practice 2018:28 de noviembre. [Ref.ID 102864]

8.

Álvarez del Vayo M. Las asociaciones de pacientes recibieron casi seis millones de euros de la industria farmacéutica en 2016. CIVIO Medicamentalia 2018:19 de abril. [Ref.ID 102833]

9.

Garde D. Alzheimer’s study sparks a new round of debate over the amyloid hypothesis. STAT Daily Recap 2018:30 de julio. [Ref.ID 102727]

10.

Garde D. Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment. STAT Daily Recap 2018:1. [Ref.ID 102726]

11.

Garde D. Biogen reports positive results with Alzheimer’s drug, reviving hopes for once-failed treatment. STAT Daily Recap 2018:1. [Ref.ID 102725]

12.

Anónimo. Synthetic cannabinoid may improve agitation and aggression in Alzheimer’s disease patients, research suggests. DIA Daily 2018:26 de julio. [Ref.ID 102724]

13.

Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Mozley LH, Vandenberghe R, Mo Y, Michelson D. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med 2018;378:3 de mayo. [Ref.ID 102593]

14.

Gray SL, Walker RL, Dublin S, Yu O, Aielo Bowles EJ, Anderson ML, Crane PK, Larson EB. Proton pump inhibitor use and dementia risk: prospective population-based study. J Am Geriatr Soc 2018;66:febrero. [Ref.ID 102537]

15.

Taipale H, Hamina A, Lampela P, Tanskanen A, Tiihonen J, Karttunen N, Tolpannen A-M, Hartikainen S. Is Alzheimer’s disease associated with previous opioid use?. Pain Med 2017:28 de agosto. [Ref.ID 102153]

16.

Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. The Lancet Public Health 2017;2:e149-56. [Ref.ID 101922]

17.

Obach M, Lopez P, Catalan A. Tratamiento farmacológico de la enfermedad de Alzheimer en la población de Catalu˜na. Med Clin (Barc) 2017;149:86-7. [Ref.ID 101905]

18.

Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia . Can Med Assoc J 2017;189:E517-518. [Ref.ID 101525]

19.

Taipale H, Tolppanen A-M, Koponen M, Tanskanen A, Lavikainen P, Sund R, Tiihonen J, Hartikainen S. Risk of pneumonia associated with incident benzodiazepine use among community- dwelling adults with Alzheimer disease. Can Med Assoc J 2017;189:E519-529. [Ref.ID 101524]

20.

Patel AN, Lee S, Andrews HF, Pelton GH, Schultz SK, Sultzer DL, Mintzer J, de la Pena D, Gupta S, Colon S, Schimming C, Levin B, Devanand DP. Prediction of relapse after discontinuation of antipsychotic treatment in Alzheimer’s disease: the role of hallucinations. Am J Psychiatry 2016:1. [Ref.ID 100993]